

115TH CONGRESS  
2D SESSION

# H. R. 5353

To amend the Public Health Service Act to reauthorize and expand a program of surveillance and education, carried out by the Centers for Disease Control and Prevention, regarding infections associated with injection drug use.

---

## IN THE HOUSE OF REPRESENTATIVES

MARCH 20, 2018

Mr. LANCE (for himself, Mr. KENNEDY, Mr. COLLINS of New York, Ms. ESHOO, Mr. BARTON, and Ms. MATSUI) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend the Public Health Service Act to reauthorize and expand a program of surveillance and education, carried out by the Centers for Disease Control and Prevention, regarding infections associated with injection drug use.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Eliminating Opioid Re-  
5 lated Infectious Diseases Act of 2018”.

1 **SEC. 2. REAUTHORIZATION AND EXPANSION OF PROGRAM**  
2 **OF SURVEILLANCE AND EDUCATION RE-**  
3 **GARDING INFECTIONS ASSOCIATED WITH IN-**  
4 **JECTION DRUG USE.**

5 Section 317N of the Public Health Service Act (42  
6 U.S.C. 247b–15) is amended to read as follows:

7 **“SEC. 317N. SURVEILLANCE AND EDUCATION REGARDING**  
8 **INFECTIONS ASSOCIATED WITH INJECTION**  
9 **DRUG USE.**

10 “(a) IN GENERAL.—The Secretary, acting through  
11 the Director of the Centers for Disease Control and Pre-  
12 vention, may (directly and through grants to public and  
13 nonprofit private entities) provide for programs to carry  
14 out the following activities:

15 “(1) To cooperate with the States in imple-  
16 menting a surveillance system to determine the inci-  
17 dence of infections associated with injection drug use  
18 and to assist the States in determining the preva-  
19 lence of such infections, including the reporting of  
20 chronic hepatitis C virus and human immuno-  
21 deficiency virus cases.

22 “(2) To identify, counsel, and offer testing to  
23 individuals who are at risk of infections as a result  
24 of injection drug use, receiving blood transfusions  
25 prior to July 1992, or other risk factors.

1           “(3) To provide appropriate referrals for coun-  
2           seling, testing, and medical treatment of individuals  
3           identified under paragraph (2) and to ensure, to the  
4           extent practicable, the provision of appropriate fol-  
5           low-up services.

6           “(4) To develop and disseminate public infor-  
7           mation and education programs for the detection  
8           and control of infections associated with injection  
9           drug use, with priority given to high-risk populations  
10          as determined by the Secretary.

11          “(5) To improve the education, training, and  
12          skills of health professionals in the detection and  
13          control of infections associated with injection drug  
14          use, with priority given to substance use disorder  
15          treatment providers, pediatricians, other primary  
16          care providers, and obstetrician-gynecologists.

17          “(b) LABORATORY PROCEDURES.—The Secretary  
18          may (directly and through grants to public and nonprofit  
19          private entities) carry out programs to provide for im-  
20          provements in the quality of clinical-laboratory procedures  
21          regarding infections associated with injection drug use.

22          “(c) DEFINITIONS.—In this section, the term ‘injec-  
23          tion drug use’ means—

1           “(1) intravenous administration of a substance  
2           in schedule I under section 202 of the Controlled  
3           Substances Act;

4           “(2) intravenous administration of a substance  
5           in schedule II, III, IV, or V under section 202 of the  
6           Controlled Substances Act that has not been ap-  
7           proved for intravenous use under—

8                   “(A) section 505 of the Federal Food,  
9                   Drug and Cosmetic Act; or

10                   “(B) section 351 of the Public Health  
11                   Service Act; or

12           “(3) intravenous administration of a substance  
13           in schedule II, III, IV, or V under section 202 of the  
14           Controlled Substances Act that has not been pre-  
15           scribed to the person using the substance.

16           “(d) AUTHORIZATION OF APPROPRIATIONS.—For the  
17           purpose of carrying out this section, there are authorized  
18           to be appropriated \$40,000,000 for each of the fiscal years  
19           2019 through 2023.”.

○